The Angiosarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Angiosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Angiosarcoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Angiosarcoma and features dormant and discontinued products.
GlobalData tracks 43 drugs in development for Angiosarcoma by 36 companies/universities/institutes. The top development phase for Angiosarcoma is phase ii with 27 drugs in that stage. The Angiosarcoma pipeline has 40 drugs in development by companies and three by universities/ institutes. Some of the companies in the Angiosarcoma pipeline products market are: Agenus, Bristol-Myers Squibb and Shenzhen Chipscreen Biosciences.
The key targets in the Angiosarcoma pipeline products market include Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, and Cytotoxic T Lymphocyte Protein 4.
The key mechanisms of action in the Angiosarcoma pipeline product include Programmed Cell Death Protein 1 Antagonist with seven drugs in Phase III. The Angiosarcoma pipeline products include ten routes of administration with the top ROA being Intravenous and eight key molecule types in the Angiosarcoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Angiosarcoma overview
Angiosarcoma is a rare type of cancer that that develops in the inner lining of the blood and lymph vessels and is linked to a gene called POTI. Angiosarcoma appears as a bruise-like lesion that grows over time. Once metastatic, it becomes difficult to treat and the survival rate drops to 12-33%.
For a complete picture of Angiosarcoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
